异位妊娠259例临床总结分析

目的探讨异位妊娠的发病相关因素,提出防治措施。方法对我院10年间收治的259例异位妊娠病例的发病趋势,既往病史及节育状况、误诊情况作一回顾分析。结果近10年异位妊娠发生率为2.19%并呈上升趋势。人工流产、节育手术、下腹部手术等与异位妊娠的发生关系密切。结论降低人工流产率,减少性病传播是预防异位妊娠发生的重要手段,随着高科技手段的应用使异位妊娠早期准确的诊断成为可能,为保守治疗赢得机会。     

自制新荧光剂EPQS的性能测试

作者对自制新荧光剂EPQS进行了性能测试。结果:量子产率为0.21;最大激发波长和荧光波长分别为375nm和484nm,stokes位移109nm;检测生物化合物常用的缓冲溶液对荧光峰位无影响,对荧光强度影响很小;温度的影响也小(18～43℃,FRI61.5～58.1),PH的影响也不大。说明EPQS不仅荧光参数好,而且稳定性也好。适合在较广泛的环境条件下使用。     

R波相关振动法血压测量

为了提高振地血压测量的准确性，提出了一咱基于心电Ｒ波与血压振动波之间相关性，识别振动信号的一种抗干扰方法＝－Ｒ波相关法，结合振动波形特征识别，该方法可有效地提取信号，消除干扰影响，该算法已在１６位８０９８单片机上实现，本文同时给出了程序的详细流程图。     

从ECCE到Phaco的转变--核处理技术的实验研究

目的通过化学方法制成动物核性白内障模型,探讨相对能量复合指数(RECP)与角膜内皮细胞活性的关系。方法将5种化学物质注入晶状体,以透过黑白条纹的清晰程度判断晶状体混浊程度并分级。然后将实验眼球分为6组(Ⅰ组为对照组;Ⅱ-Ⅵ为实验组),行标准超声乳化白内障摘除手术。手术后立即取下角膜,作锥蓝-茜素红联合染色标本和扫描电镜标本。结果晶状体内注入甲醛、冰醋酸、无水乙醇、丙酮和苯扎溴铵均能形成晶状体混浊,其中:冰醋酸致晶状体混浊能力最弱,无水乙醇、丙酮次之,甲醛、苯扎溴铵最强。当RECP≤90时,锥蓝-茜素红双重染色和扫描电镜均表明角膜内皮细胞活性好,其形态和细胞联接均无改变。当RECP=120时,角膜内皮细胞形态尚正常,但是细胞联结和胞膜部分破坏。当RECP=150时,角膜内皮细胞严重损伤。结论用化学方法制作核性白内障模型供过渡训练使用是可行的。当RECP超过某一数值(>90)时,即与角膜内皮细胞的活性成负相关。     

髂骨截骨延长术下肢延长量计算方法的探讨

髂骨截骨延长术下肢的延长量及其测算方法报道不一。根据手术的生物力学原理和肢体延长的机理,认为肢体的延长量是由患肢绝对延长和相对延长两部分组成的,它与髂骨截骨间距密切相关,经数学推算,其方法为测量X线片髂骨截骨撑开的梯形中心间距(cm),减去X线片的放大值(cm)再除以0.7;手术时髂骨需要撑开的宽度(cm)为肢体短缩数(cm)乘以0.7。经临床103例手术验证,这种计算方法是准确的。     

Efficacy I: a new method for estimating relative efficacy of full agonists via a newly defined efficacy related parameter

A new method for estimating relative efficacies and relative intrinsic efficacies of agonists is described. Relative efficacy is estimated by employing a newly defined efficacy related parameter (e^ES) and it may be estimated without prior knowledge of efficacy values or the value of the equilibrium dissociation constants, K_A, of agonist-receptor complexes. The parameter e^ES is directly related to efficacy (e) and is defined as the ratio of maximal stimulus to maximal effect of an agonist. The value of e^ES indicates whether or not spare receptors are present for a particular agonist–effector system. The e^ES values of agonists are estimated by utilizing submaximal concentration–effect curves determined with fixed agonist-competitive antagonist concentration combinations and choosing a suitable reference (height of an agonistic concentration–effect curve) to which the height of the stimulus concentration–effect curves of the agonist may be compared. In addition to e^ES, other new agonist–effector parameters, namely S_Em/S_m and φ_min, were also defined.     

Breast cancer risk with postmenopausal hormonal treatment

This review was designed to determine from the best evidence whether there is an association between postmenopausal hormonal treatment and breast cancer risk. Also, if there is an association, does it vary according to duration and cessation of use, type of regimen, type of hormonal product or route of administration; whether there is a differential effect on risk of lobular and ductal cancer; and whether hormone treatment is associated with breast cancers that have better prognostic factors? Data sources for the review included Medline, the Cochrane Database of Systematic Reviews (Cochrane Library, 2005) and reference lists in the identified citations. Eligible citations addressed invasive breast cancer risk among postmenopausal women and involved use of the estrogen products with or without progestin that are used as treatment for menopausal symptoms. Abstracted data were demographic groupings, categories of hormone use, categories of breast cancer, two-by-two tables of exposure and outcome and adjusted odds ratios, relative risks (RRs) or hazard rates. Average estimates of risk were weighted by the inverse variance method, or if heterogeneous, using a random effects model. The average risk of invasive breast cancer with estrogen use was 0.79 [95% confidence interval (95% CI) = 0.61-1.02] in four randomized trials involving 12 643 women. The average breast cancer risk with estrogen-progestin use was 1.24 (95% CI = 1.03-1.50) in four randomized trials involving 19 756 women. The average risks reported in recent epidemiological studies were higher: 1.18 (95% CI = 1.01-1.38) with current use of estrogen alone and 1.70 (95% CI = 1.36-2.17) with current use of estrogen-progestin. The association of breast cancer with current use was stronger than the association with ever use, which includes past use. For past use, the increased breast cancer risk diminished soon after discontinuing hormones and normalized within 5 years. Reasonably adequate data do not show that breast cancer risk varies significantly with different types of estrogen or progestin preparations, lower dosages or different routes of administration, although there is a small difference between sequential and continuous progestin regimens. Epidemiological studies indicate that estrogen-progestin use increases risk of lobular more than ductal breast cancer, but the number of studies and cases of lobular cancer remains limited. Among important prognostic factors, the stage and grade in breast cancers associated with hormone use [corrected] do not differ significantly from those in non-users, but breast cancers in estrogen-progestin users are significantly more likely to be estrogen receptor (ER) positive. In conclusion, valid evidence from randomized controlled trials (RCTs) indicates that breast cancer risk is increased with estrogen-progestin use more than with estrogen alone. Epidemiological evidence involving more than 1.5 million women agrees broadly with the trial findings. Although new studies are unlikely to alter the key findings about overall breast cancer risk, research is needed, however, to determine the role of progestin, evaluate the risk of lobular cancer and delineate effects of hormone use on receptor presence, prognosis and mortality in breast cancer.     

Bestimmung der biologischen Aktivität von synthetischem Secretin

Zusammenfassung Die relative Wirksamkeit von synthetischem Secretin (Wünsch) und reinem natürlichen Secretin ohne Zusatz von Cysteinhydrochlorid (Mutt) sowie von reinem natürlichem Secretin mit Zusatz von Cysteinhydrochlorid (G.I.H. Research Unit) wurde am Parameter der Volumen-und Bicarbonatsekretion des Pankreas bei 10 narkotisierten Bastardhunden geprüft. Die relative Wirksamkeit von synthetischem Secretin liegt — bezogen auf Gewichtsbasis — bei 100% gegenüber natürlichem (Mutt) (Parameter: Volumen- und Bicarbonatsekretion). Die biologische Aktivität von synthetischem Secretin beträgt ungefähr 3,58 klin. E/µg (Parameter: Volumensekretion) bzw. 3,88 klin. E/µg (Parameter: Bicarbonatsekretion) gegenüber dem Secretin mit Zusatz von Cysteinhydrochlorid (G.I.H. Research Unit). Natürliches Secretin (Mutt) hat eine biologische Aktivität gegenüber dem Secretin mit Zusatz von Cysteinhydrochlorid (G.I.H. Research Unit) von annähernd 3,52 klin. E/µg (Parameter: Volumensekretion) bzw. 3,48 klin. E/µg (Parameter: Bicarbonatsekretion).Durchgeführt mit Unterstützung der Deutschen Forschungsgemeinschaft.